Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation

European Journal of Pharmaceutical Sciences

Volumn 53, Issue 1, 2014, Pages 109-117

  Zu, Yuangang ^a   Sun, Wei ^a   Zhao, Xiuhua ^a   Wang, Weiguo ^a   Li, Yong ^a   Ge, Yunlong ^a   Liu, Ying ^a   Wang, Kunlun ^a  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Amphotericin B; Characterization; LAP; Nanoparticles; Oral; Preparation

Indexed keywords

AMPHOTERICIN B; NANOPARTICLE; SOLVENT;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; THERMOGRAVIMETRY; X RAY DIFFRACTION;

AMPHOTERICIN B; CHARACTERIZATION; LAP; NANOPARTICLES; ORAL; PREPARATION;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHEMICAL PRECIPITATION; DIMETHYL SULFOXIDE; DRUG COMPOUNDING; FREEZE DRYING; NANOPARTICLES; POLOXAMER; POLYSORBATES; SOLUBILITY; SOLVENTS; SURFACE-ACTIVE AGENTS; TEMPERATURE;

EID: 84892758041     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.12.005     Document Type: Article

References (30)

1. A. Antoniadou, and B. Dupont Lipid formulations of amphotericin B: Where are we today? J. Mycol. Med. 15 2005 230 238
2. H. Chiou, L. Li, T. Hu, H. Chan, J. Chen, and J. Yun Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation Int. J. Pharm. 331 2007 93 98
3. E. Cho, W. Cho, K.-H. Cha, J. Park, M.-S. Kim, J.-S. Kim, H.J. Park, and S.-J. Hwang Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives Int. J. Pharm. 396 2010 91 98
4. S. Das, and P.K. Suresh Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B Nanomedicine: Nanotechnol., Biol. Med. 7 2011 242 247
5. N.M. Deshpande, M.G. Gangrade, M.B. Kekare, and V.V. Vaidya Determination of free and liposomal amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques J. Chromatogr. B 878 2010 315 326
6. Y. Dong, W.K. Ng, J. Hu, S. Shen, and R.B.H. Tan A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs Int. J. Pharm. 386 2010 256 261
7. A. Falamarzian, and A. Lavasanifar Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(ε-caprolactone) based nano-carriers for the solubilization and delivery of amphotericin B Colloids Surf., B 81 2010 313 320
8. H. Fukui, T. Koike, T. Nakagawa, A. Saheki, S. Sonoke, Y. Tomii, and J. Seki Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commercial lipid-based formulations Int. J. Pharm. 267 2003 101 112
9. J. Hu, W.K. Ng, Y. Dong, S. Shen, and R.B.H. Tan Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying Int. J. Pharm. 404 2011 198 204
10. F. Ibrahim, P. Gershkovich, O. Sivak, E.K. Wasan, and K.M. Wasan Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model Eur. J. Pharm. Sci. 46 2012 323 328
11. J.L. Italia, M.M. Yahya, D. Singh, and M.N.V. Ravi Kumar Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous fungizone® Pharmaceut. Res. 26 2009 1324 1331
12. C.L. Jaffe, E.K. Wasan, P. Gershkovich, J. Zhao, X. Zhu, K. Werbovetz, R.R. Tidwell, J.G. Clement, S.J. Thornton, and K.M. Wasan A novel tropically stable oral amphotericin B formulation (ico-010) exhibits efficacy against visceral leishmaniasis in a murine model Plos. Neglected Tropical Diseases 4 2010 e913
13. O. Kayser, C. Olbrich, V. Yardley, A.F. Kiderlen, and S.L. Croft Formulation of amphotericin B as nanosuspension for oral administration Int. J. Pharm. 254 2003 73 75
14. J.-S. Kim, M.-S. Kim, H.J. Park, S.-J. Jin, S. Lee, and S.-J. Hwang Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process Int. J. Pharm. 359 2008 211 219
15. M. Kleinberg What is the current and future status of conventional amphotericin B? Int. J. Antimicrob. Agents 27 2006 12 16
16. P. Kocbek, S. Baumgartner, and J. Kristl Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs Int. J. Pharm. 312 2006 179 186
17. A. Lemke, A.F. Kiderlen, B. Petri, and O. Kayser Delivery of amphotericin B nanosuspensions to the brain and determination of activity against Balamuthia mandrillaris amebas Nanomedicine: Nanotechnol., Biol., Med. 6 2010 597 603
18. Y. Li, X. Zhao, Y. Zu, X. Han, Y. Ge, W. Wang, and X. Yu A novel active targeting preparation, vinorelbine tartrate (VLBT) encapsulated by folate-conjugated bovine serum albumin (BSA) nanoparticles: preparation, characterization and in vitro release study Materials 5 2012 2403 2422
19. T.-S. Lin, C.-C. Chuang, H.-L. Hsu, Y.-T. Liu, W.-P. Lin, C.-C. Liang, and W.-T. Liu Role of amphotericin B upon enhancement of protective immunity elicited by oral administration with liposome-encapsulated-Japanese encephalitis virus nonstructural protein 1 (NS1) in mice Microb. Pathog. 49 2010 67 74
20. Y. Oz, A. Kiremitci, I. Dag, S. Metintas, and N. Kiraz Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates Med. Mycol. 51 2013 60 65
21. G.H. Pereira, D.A. de Angelis, R.A. Brasil, M.D. Martins, D.D.C.E. Silva, M.W. Szeszs, and M.D.C. Melhem Disseminated amphotericin-resistant fusariosis in acute leukemia patients: report of two cases Mycopathologia 175 2013 107 114
22. K. Sachs-Barrable, S.D. Lee, E.K. Wasan, S.J. Thornton, and K.M. Wasan Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections Adv. Drug. Deliver Rev. 60 2008 692 701
23. C. Salerno, D.A. Chiappetta, A. Arechavala, S. Gorzalczany, S.L. Scioscia, and C. Bregni Lipid-based microtubes for topical delivery of amphotericin B Colloids Surf., B 107 2013 160 166
24. S. Sheikh, S.M. Ali, M.U. Ahmad, A. Ahmad, M. Mushtaq, M. Paithankar, J. Mandal, D. Saptarishi, A. Sehgal, K. Maheshwari, and I. Ahmad Nanosomal amphotericin B is an efficacious alternative to Ambisome® for fungal therapy Int. J. Pharm. 397 2010 103 108
25. H. Van de Ven, C. Paulussen, P.B. Feijens, A. Matheeussen, P. Rombaut, P. Kayaert, G. Van den Mooter, W. Weyenberg, P. Cos, L. Maes, and A. Ludwig PLGA nanoparticles and nanosuspensions with amphotericin B: Potent in vitro and in vivo alternatives to Fungizone and Am Bisome J. Control Release 161 2012 795 803
26. Z. Wang, J.F. Chen, Y. Le, Z.G. Shen, and J. Yun Preparation of ultrafine beclomethasone dipropionate drug powder by antisolvent precipitation Ind. Eng. Chem. Res. 46 2007 4839 4845
27. E.K. Wasan, Karen, B. Bartlett, Pavel Gershkovich, O. Sivak, B. Banno, Z. Wong, J. Gagnon, B. Gates, C.G. Leon, and K.M. Wasan Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigarus or Candida albicans Int. J. Pharm. 372 2009 76 84
28. S.-D. Yeo, and J.-C. Lee Crystallization of sulfamethizole using the supercritical and liquid antisolvent processes J. Supercrit. Fluids 30 2004 315 323
29. H.X. Zhang, J.X. Wang, Z.B. Zhang, Y. Le, Z.G. Shen, and J.F. Chen Micronization of atorvastatin calcium by antisolvent precipitation process Int. J. Pharm. 374 2009 106 113
30. W.Z. Zhu, J.X. Wang, L. Shao, H.X. Zhang, Q.X. Zhang, and J.F. Chen Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microchannel reactor Int. J. Pharm. 395 2010 260 265